In a study of patients with type 2 diabetes and chronic kidney disease, canagliflozin, an SGLT2 inhibitor, decreased the risk of end-stage renal disease by 32% compared with placebo.
All articles by Jody Charnow
In a Finnish study, the cumulative risk for end-stage renal disease among patients with newly diagnosed with type 2 diabetes was less than 1% at 20 years.
Hypomagnesemia after a kidney transplant is associated with a 58% increased risk of new-onset diabetes.
Hemodialysis patients who undergo the procedure experience decreased risks of all-cause and cardiovascular mortality.
Prostate cancer is more likely to be found in men with low testosterone vs. those with normal levels.
Recipients of diabetic donor kidneys—especially diabetic recipients—are at increased risk of graft loss and death.
Researchers find an independent association between subclinical hypothyroidism and diabetic nephropathy in type 2 diabetes.